slides · global inventory
Sequoia Pitch
Arc collection for the active corpus filters, with each row opening the slide detail view.
Matching slides 43,093
Current window 26,671-26,700
Pages 1,437
Rows per page 30
Arc
26,671-26,700 of 43,093
15
The slide uses a three-row layout to categorize ESG efforts into Environmental, Social, and Governance pillars.Moelis & Company | Investor Presentation Deck | 24 slides · Moelis
Conference presentation Investor relations Beat · Market SizeLoop · Golden Circle1 hit
19
The 2023 pre-tax margin shows a negative value due to significant investment in Managing Director hires.Moelis & Company | Investor Presentation Deck | 24 slides · Moelis
Conference presentation Investor relations Beat · FinancialsLoop · Golden Circle1 hit
20
Moelis & Company | Investor Presentation Deck | 24 slidesMoelis & Company | Investor Presentation Deck | 24 slides · Moelis
Conference presentation Investor relations Beat · FinancialsLoop · Golden Circle1 hit
21
The chart illustrates a consistent history of capital return, with the 2021 peak being particularly notable.Moelis & Company | Investor Presentation Deck | 24 slides · Moelis
Conference presentation Investor relations Beat · FinancialsLoop · Golden Circle1 hit
22
The chart shows Moelis significantly outperforming the other indices with a 356% return.Moelis & Company | Investor Presentation Deck | 24 slides · Moelis
Conference presentation Investor relations Beat · FinancialsLoop · Golden Circle1 hit
09
The slide highlights the lack of clear standard of care in later lines of therapy, framing the problem for a potential new therapeutic intervention.Nuvalent | Investor Presentation Deck | 42 slides · Nuvalent
Pitch deck Investor relations Beat · ProblemLoop · Pattern Hunter1 hit
10
The slide uses a 'Case Study' framework to validate the strategy by comparing it to the established success of Osimertinib in EGFR+ NSCLC.Nuvalent | Investor Presentation Deck | 42 slides · Nuvalent
Pitch deck Investor relations Beat · SolutionLoop · Pattern Hunter1 hit
11
The slide uses a bar chart to segment the $3.1B market into specific drugs and categories.Nuvalent | Investor Presentation Deck | 42 slides · Nuvalent
Pitch deck Investor relations Beat · Market SizeLoop · Pattern Hunter1 hit
17
Includes detailed patient enrollment table by dose cohort and trial objectives.Nuvalent | Investor Presentation Deck | 42 slides · Nuvalent
Pitch deck Investor relations Beat · TractionLoop · Cost Of Inaction1 hit
18
Data cut-off: 8 Aug 2023. Includes detailed breakdown of prior ALK TKI lines and specific mutations.Nuvalent | Investor Presentation Deck | 42 slides · Nuvalent
Pitch deck Investor relations Beat · TractionLoop · Cost Of Inaction1 hit
19
Data from ALKOVE-1 Phase 1 trial, presented at AACR-NCI-EORTC 2023.Nuvalent | Investor Presentation Deck | 42 slides · Nuvalent
Pitch deck Investor relations Beat · TractionLoop · Cost Of Inaction1 hit
20
The slide uses a standard oncology 'swimmer' or 'waterfall' plot format to demonstrate drug efficacy across different patient cohorts.Nuvalent | Investor Presentation Deck | 42 slides · Nuvalent
Pitch deck Investor relations Beat · TractionLoop · Cost Of Inaction1 hit
21
Swimmer plot showing patient-level treatment duration with ongoing status and response markers.Nuvalent | Investor Presentation Deck | 42 slides · Nuvalent
Pitch deck Investor relations Beat · Traction1 hit
22
Includes two patient case studies with MRI scans showing baseline vs follow-up results.Nuvalent | Investor Presentation Deck | 42 slides · Nuvalent
Pitch deck Investor relations Beat · Traction1 hit
23
Data cut-off: 8 Aug 2023. Source: Lin J.J. et al., AACR-NCI-EORTC 2023.Nuvalent | Investor Presentation Deck | 42 slides · Nuvalent
Pitch deck Investor relations Beat · Traction1 hit
24
The chart shows pharmacokinetic data across five dose cohorts, demonstrating that the 150mg dose consistently stays above the predicted CNS efficacy thresholds.Nuvalent | Investor Presentation Deck | 42 slides · Nuvalent
Pitch deck Investor relations Beat · Traction1 hit
25
The slide uses a three-column layout to segment the market by treatment line (3L+, 2L, 1L) and map the drug's value proposition to each.Nuvalent | Investor Presentation Deck | 42 slides · Nuvalent
Pitch deck Investor relations Beat · Traction1 hit
26
Includes a detailed table of patient cohorts and study objectives.Nuvalent | Investor Presentation Deck | 42 slides · Nuvalent
Pitch deck Investor relations Beat · Traction1 hit
27
The slide uses a sidebar 'AT A GLANCE' to summarize key clinical and regulatory status.Nuvalent | Investor Presentation Deck | 42 slides · Nuvalent
Pitch deck Investor relations Beat · Traction1 hit
28
The slide uses a timeline-based framework to contrast treatment options with clinical limitations.Nuvalent | Investor Presentation Deck | 42 slides · Nuvalent
Pitch deck Investor relations Beat · Traction1 hit
29
The slide uses a matrix-like structure to compare NVL-520's clinical profile against five competitors (Crizotinib, Entrectinib, Lorlatinib, Repotrectinib, Taletrectinib).Nuvalent | Investor Presentation Deck | 42 slides · Nuvalent
Pitch deck Investor relations Beat · Traction1 hit
30
Slide presents three distinct preclinical data sets: IC50 viability assays, brain:plasma ratio, and selectivity index vs TRKB.Nuvalent | Investor Presentation Deck | 42 slides · Nuvalent
Pitch deck Investor relations Beat · Traction1 hit
31
The slide presents a summary of a clinical trial, including patient eligibility criteria and a breakdown of patient cohorts by dose level.Nuvalent | Investor Presentation Deck | 42 slides · Nuvalent
Pitch deck Investor relations Beat · Traction1 hit
32
Data presented in two tables: Patient Characteristics and Treatment History.Nuvalent | Investor Presentation Deck | 42 slides · Nuvalent
Pitch deck Investor relations Beat · Traction1 hit
33
Includes a summary table of ORR and a waterfall plot of tumor regression.Nuvalent | Investor Presentation Deck | 42 slides · Nuvalent
Pitch deck Investor relations Beat · Traction1 hit
34
Includes specific patient subgroup metrics (ORR, tumor shrinkage) and longitudinal imaging.Nuvalent | Investor Presentation Deck | 42 slides · Nuvalent
Pitch deck Investor relations Beat · Traction1 hit
35
Data as of 13 Sep 2022. Includes list of specific adverse events by grade.Nuvalent | Investor Presentation Deck | 42 slides · Nuvalent
Pitch deck Investor relations Beat · Traction1 hit
36
RP2D = Recommended Phase 2 Dose; QD = once daily; MTD = Maximum Tolerated Dose.Nuvalent | Investor Presentation Deck | 42 slides · Nuvalent
Pitch deck Investor relations Beat · Traction1 hit
05
The slide uses a circular process flow (Assess, Prescribe, Dispense, Administer) surrounding a central 'One Platform' concept.Omnicell | Investor Presentation Deck | 27 slides · Omnicell
Conference presentation Investor relations Beat · Solution1 hit
06
The slide uses a circular icon-grid layout to present a set of aspirational goals.Omnicell | Investor Presentation Deck | 27 slides · Omnicell
Conference presentation Investor relations Beat · ProblemLoop · Cost Of Inaction1 hit